Navigation Links
Optimer Pharmaceuticals, Inc. Announces Presentation at ECCMID of Post-Hoc Subgroup Analysis of DIFICID in Adult Cancer Patients Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)
Date:3/30/2012

SAN DIEGO, March 30, 2012 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) announced the presentation of results from a post-hoc subgroup analysis of the company's two large Phase 3 trials which demonstrated that cancer patients with Clostridium difficile-associated diarrhea (CDAD) had higher clinical cure rates, better sustained response and lower recurrence when treated with DIFICID® (fidaxomicin) tablets compared to oral vancomycin. The data will be presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in London.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

The analysis included 153 patients with active cancer who were treated in the two DIFICID Phase 3 studies and who received 8 days or more of treatment with DIFICID or oral vancomycin. In the overall combined population, patients with cancer had significantly lower cure and sustained response rates than patients without cancer. DIFICID was five times more likely than vancomycin to produce a clinical response and three times more likely to lead to a sustained response, while patients treated with vancomycin had a 2.6 fold greater risk of experiencing recurrence. Specifically, DIFICID provided superior response compared to vancomycin across all clinical endpoints studied: clinical response (97.3% vs. 87.5%, 95% CI 1.07-23.98; p=0.041), sustained response (83.6% vs. 61.3%, 95% CI 1.50-6.91; p=0.003) and disease recurrence (14.1% vs. 30.0%, 95% CI 0.16-0.89; p=0.025). Furthermore, cancer patients who were treated with DIFICID in the clinical studies had similar cure, recurrence and sustained response rates as non-cancer patients who received the drug, while cancer patients treated with vancomycin tended to have poorer outcomes than non-cancer patients. The ov
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
2. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
3. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
4. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
5. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
8. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
9. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
10. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
11. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Calif. , Jan. 15, 2014 Massachusetts ... (NASDAQ: AMGN ) announced today that ... discover and validate new therapeutic targets and develop ... chronic disorder that affects millions worldwide. The MGH-Broad-Amgen ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... June 2, 2011 Goodwin Biotechnology, ... process development and GMP manufacturing of cell culture ... company focused on monoclonal antibody development with a ... discovery platform, announced a collaboration on the development ...
... Kendle (Nasdaq: KNDL ), a ... announced the appointment of Robert Shepard, MD, FACP, ...  Dr. Shepard is a leading authority on clinical ... of oncology research experience to Kendle. He will ...
Cached Medicine Technology:Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics 2Goodwin Biotechnology Announces a Collaboration With Alethia Biotherapeutics 3Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology 2Kendle Appoints Robert Shepard, MD, FACP Executive Director, Oncology 3
(Date:4/17/2014)... Colic affects about one in five infants in the ... during the first several months after birth. Research into ... promise; however, the April 1, 2014 issue of the ... on a study, "Probiotics and Infant Colic," concluding that ... for infant colic did not reduce crying or ...
(Date:4/17/2014)... to ward off depression among retirees, particularly among those ... The Journals of Gerontology, Series B: Psychological ... " Internet Use and Depression Among Retired Older Adults ... authors report that Internet use reduced the probability of ... sample. , Late-life depression affects between 5 and ...
(Date:4/17/2014)... Massage therapy improves general blood flow and alleviates ... by researchers at the University of Illinois at ... of print in the Archives of Physical ... improved vascular function in people who had not ... regardless of their level of physical activity. , ...
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... HAMPTON, NJ (April 16, 2014): Celldex Therapeutics, Inc. ... Phase 1 study of CDX-1401 in solid tumors, including ... Translational Medicine (Vol 6 Issue 232). The data ... of clinical benefit in patients with very advanced cancers ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Internet use may cut retirees' depression 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... , SHENZHEN, China, Nov. ... http://www.beikebiotech.com ), China,s leading stem cell ... entered into an,agreement with Yokohama-based Biomaster Inc. ( ... technologies. Biomaster specializes in research,and commercialization of ...
... , COLUMBIA, S.C., Nov. 5 Companion Life Insurance ... facilitator to offer its dental policyholders preferred pricing on ... States. , Traveling abroad for credentialed dental care, also ... benefits. Prices at the international clinics average 60 to ...
... improvement, study finds, , THURSDAY, Nov. 5 (HealthDay News) -- ... make a good night,s sleep come more easily. , A ... that the odds of having disturbed sleep in the seven ... seven years before they stopped working. , Sleep improvements probably ...
... International Corporation (Nasdaq: PRXL ), a leading ... has established The Expert Office(TM) at PAREXEL. ... a single point of contact for clients to ... the Company,s leading medical, therapeutic area, regulatory, and ...
... ... published on GlucoStories.com , ... Pompano Beach, Fla. (PRWEB) November 5, 2009 --Today, American Diabetes Wholesale is asking ... will donate $3.00 for every story published on GlucoStories.com to diabetes organizations. The company’s ...
... ... for Thailand to become Asia,s medical hub is becoming a reality as Thailand continues to ... sector, ahead of the county,s GDP, the Tourism Authority of Thailand (TAT) and the Department ... lower medical treatments by 2010. , ...
Cached Medicine News:Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 2Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 3Health News:Beike Biotechnology Invests in Leading Japanese Regenerative Medicine Co., Biomaster Inc. 4Health News:Companion Life Adds Dental Tourism Option to Help Policyholders Save 2Health News:Companion Life Adds Dental Tourism Option to Help Policyholders Save 3Health News:Without Job Stress, Retirees Sleep Better 2Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 2Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 3Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 4Health News:PAREXEL Introduces The Expert Office(TM) -- Offering Enhanced Access to Comprehensive Expertise to Meet Strategic Partnering Needs 5Health News:GlucoStories Donation Campaign Aims to Raise Diabetes Awareness and Money for Diabetes Causes 2Health News:Thailand's Medical Tourism is Booming - Thailand on its Way to Become Asia's Medical Hub 2Health News:Thailand's Medical Tourism is Booming - Thailand on its Way to Become Asia's Medical Hub 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: